Merck & Co., Inc. (MRK) – Strong hopes from COVID 19 antiviral drug

Merck and Ridgeback developed an oral COVID 19 antiviral drug, Molnupiravir which can reduce the risk of hospitalization or death by ~50% compared to Placebo for patients with mild or moderate COVID 19, as showed in positive interim analysis of phase 3 study.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance 

CrispIdea Coverage

No of Pages : 45